Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cell (gdTCR+ invTCR+ NKT-like cell)
- Target
- gdTCR+ invTCR+ NKT-like cell
- Molecular classification
- Lymphocyte, T cell, Natural Killer T cell, Receptor, T-cell receptor (TCR), gamma delta T-cell receptor (γδTCR), invariant αβTCR, NK receptor
01
Overview
Endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells are a unique population of immune cells that co-express a bispecific gamma delta (γδ) T-cell receptor (TCR), an invariant αβTCR, and Natural Killer (NK) cell-like features. These cells exhibit potent antitumor activity through direct cytotoxicity, recognition of stress-induced ligands, and cytokine production, making them attractive candidates for cancer immunotherapy.
- Other names
- Bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cellγδTCR+ invαβTCR+ NKT-like cellNKT-like cells with bispecific γδTCR and invαβTCR
02
Mechanism of action
Tumor cell lysis via TCR and NK receptor-mediated recognition; cytokine-mediated immune activation
03
Biological functions
Tumor recognitionTumor cell killingCytokine productionImmune responseCell-mediated cytotoxicity
04
Disease associations
CancerHematologic malignanciesSolid tumors
05
Safety considerations
Cytokine release syndromeOff-target toxicity
06
Interacting drugs
AVM0703
1 more in the full profile.
07
Biomarkers
Expression levels of γδTCRExpression levels of invariant αβTCRExpression levels of NK cell markersCytokine production upon activation
Beyond the preview
Go deeper on Endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cell (gdTCR+ invTCR+ NKT-like cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cell (gdTCR+ invTCR+ NKT-like cell).